Imatinib mesylate (gleevec) hepatotoxicity.
Mindikoglu
Ayse L
AL
Center for Liver Diseases, Division of Hepatology, University of Miami Leonard M Miller School of Medicine, Miami, FL 33136, USA.
Regev
Arie
A
Bejarano
Pablo A
PA
Martinez
Enrique J
EJ
Jeffers
Lennox J
LJ
Schiff
Eugene R
ER
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D001549:Benzamides; D001663:Bilirubin / Q000097:blood; D001772:Blood Cell Count; D004909:Erythrocyte Indices; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D017093:Liver Failure / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D009336:Necrosis; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011517:Prothrombin Time; D011743:Pyrimidines / Q000009:adverse effects*; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin